Menopur (Menotrophin)

Menotropin contains follicle‑stimulating hormone (FSH) and luteinising hormone (LH) activity. It binds to FSH receptors on ovarian granulosa cells and LH receptors on theca cells, promoting follicular growth, estrogen production, and ultimately triggering ovulation, which is essential for fertility treatments.

The dose of Menopur is individualized. A qualified prescriber determines the amount, frequency and duration based on the patient’s ovarian reserve, treatment protocol and response to monitoring, ensuring optimal efficacy and safety.

Menopur is not intended for use during an established pregnancy and should be discontinued if pregnancy occurs. Safety data for breastfeeding are limited; therefore, the medication is generally avoided while nursing unless the prescriber decides the benefits outweigh potential risks.

To order Menopur, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Menopur provides a combined FSH and LH activity in a single preparation, which can simplify dosing compared with separate FSH‑only products. Some clinicians prefer Menopur for patients needing both hormones, while others may choose recombinant FSH alone for more precise dose titration. The choice depends on individual patient characteristics and protocol preferences.

Menopur should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use, and discard any solution that appears discoloured or contains particles.

Menopur is supplied as a powder for solution that is reconstituted with sterile water. The resulting solution is injected either intramuscularly or subcutaneously, following the prescriber’s instructions regarding injection site, technique and timing relative to other medications.

The most serious risks include severe ovarian hyperstimulation syndrome (OHSS), which can lead to fluid accumulation, thromboembolic events, and, in rare cases, anaphylactic reactions. Prompt medical attention is required if symptoms such as rapid weight gain, severe abdominal pain, shortness of breath or allergic signs develop.

Menopur is contraindicated in women who are already pregnant, have active ovarian cysts, uncontrolled thyroid disease, severe ovarian hyperstimulation syndrome, or known hypersensitivity to any component of the product. It should also be used with caution in patients with a history of thromboembolic disorders.